Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality.
Olorunfemi A OshagbemiFrits M E FranssenDionne C W BraekenYvonne HenskensEmiel F M WoutersAnke H Maitland-van der ZeeAndrea M BurdenFrank de VriesPublished in: Pharmacoepidemiology and drug safety (2018)
COPD-related acute exacerbations or hospitalisations/accident and emergency visits were not reduced with eosinophilia among users of ICS with COPD. However, all-cause mortality was reduced by 12% to 24%. These findings are potentially important and require further evaluation in prospective studies.